StreetInsider.com News Articles

Form SCHEDULE 13G MANNKIND CORP Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 10:47:00 -0400

si-local-file:///var/storage/secattach/20260731/26848469.html

Form SCHEDULE 13G MANNKIND CORP Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 10:47:00 -0400

si-local-file:///var/storage/secattach/20260731/26848469.html

MannKind (MNKD) PT Raised to $14 at Wells Fargo

Thu, 30 Jul 2026 08:35:18 -0400

Wells Fargo analyst Ben Burnett raised the price target on MannKind (NASDAQ: MNKD) to $14.00 (from $11.00) while maintaining a Overweight rating.

H.C. Wainwright Reiterates Buy Rating on MannKind (MNKD)

Thu, 30 Jul 2026 06:52:26 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $10.00 price target on MannKind (NASDAQ: MNKD).

The analyst commented: "We view INFLO-1 as supportive of the nintedanib DPI development program, with the results addressing the near-term question of whether repeated dry-powder administration is tolerated in patients with IPF. The absence of bronchospasm, pulmonary-function changes or treatment discontinuations is encouraging, while the cough observed was generally mild or moderate and transient. Although seven days of treatment cannot establish the expected long-term gastrointestinal or pulmonary tolerability profile, and no efficacy conclusions can be drawn, we view the clean AE profile as a

MannKind's inhaled nintedanib trial meets primary safety goal in IPF

Wed, 29 Jul 2026 06:30:16 -0400

MannKind Corporation (Nasdaq: MNKD) announced positive topline results from INFLO-1, its Phase 1b clinical study evaluating an inhaled dry powder formulation of nintedanib in patients with idiopathic pulmonary fibrosis (IPF), according to a company statement.

The randomized, double-blind, placebo-controlled study enrolled 27 patients across 10 U.S. sites and met its primary objective of demonstrating that nintedanib dry powder inhalation (DPI) was generally safe and well tolerated. Two multiple-ascending dose regimens were evaluated over seven days.

Key findings included no serious adverse events, no drug-related gastrointestinal side effects such as diarrhea, nausea, or vomiting, no bronchospasm events, and no treatment discontinuations or dose

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

Wed, 29 Jul 2026 06:30:00 -0400

Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations
90% of patients had no [60%] or mild [30%] cough
~450 total inhalations administered in patients with IPF
Global Phase 2 INFLO-2 trial actively enrolling patients
Conference call and webcast scheduled for July 29 at 4:30 p.m. ET

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced positive topline results from INFLO-1, its Phase 1b randomized, double-blind, placebo-controlled study evaluating

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

Wed, 29 Jul 2026 06:30:00 -0400

Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations
90% of patients had no [60%] or mild [30%] cough
~450 total inhalations administered in patients with IPF
Global Phase 2 INFLO-2 trial actively enrolling patients
Conference call and webcast scheduled for July 29 at 4:30 p.m. ET

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

Wed, 29 Jul 2026 06:30:00 -0400

Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations
90% of patients had no [60%] or mild [30%] cough
~450 total inhalations administered in patients with IPF
Global Phase 2 INFLO-2 trial actively enrolling patients
Conference call and webcast scheduled for July 29 at 4:30 p.m. ET

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

Wed, 29 Jul 2026 06:30:00 -0400

Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations
90% of patients had no [60%] or mild [30%] cough
~450 total inhalations administered in patients with IPF
Global Phase 2 INFLO-2 trial actively enrolling patients
Conference call and webcast scheduled for July 29 at 4:30 p.m. ET

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

Tue, 28 Jul 2026 16:01:00 -0400

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that the Company will report second quarter 2026 financial results after market close on Wednesday, August 5, 2026.

MannKind’s management team will host a conference call at 4:30 p.m. Eastern Time to review the financial results and provide a business update.

The webcast of the conference call will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will be available in the same location within 24 hours following the call and will

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

Tue, 28 Jul 2026 16:01:00 -0400

MannKind’s management team will host a conference call at 4:30 p.m. Eastern Time to review the financial results and provide a business update.

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

Tue, 28 Jul 2026 16:01:00 -0400

MannKind’s management team will host a conference call at 4:30 p.m. Eastern Time to review the financial results and provide a business update.

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

Tue, 28 Jul 2026 16:01:00 -0400

MannKind’s management team will host a conference call at 4:30 p.m. Eastern Time to review the financial results and provide a business update.

H.C. Wainwright Reiterates Buy Rating on MannKind (MNKD)

Mon, 27 Jul 2026 06:49:25 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $10.00 price target on MannKind (NASDAQ: MNKD).

The analyst commented: "We view FDA approval of FUROSCIX ReadyFlow as a significant positive for MNKD and validation of our view that MNKD stock remains significantly undervalued at current levels. ReadyFlow converts FUROSCIX from an effective but relatively cumbersome five-hour wearable treatment into a familiar autoinjector that delivers an IV-equivalent 80 mg dose of subcutaneous furosemide in under ten seconds. While we believe the existing outpatient prescriber base can support early adoption, we expect the larger opportunity to build over time as ReadyFlow becomes

Form 8-K MANNKIND CORP For: Jul 23

Fri, 24 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260724/26813460.html

Form 8-K MANNKIND CORP For: Jul 23

Fri, 24 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260724/26813460.html

H.C. Wainwright Reiterates Buy Rating on MannKind (MNKD)

Fri, 24 Jul 2026 07:27:22 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $10.00 price target on MannKind (NASDAQ: MNKD).

The analyst commented: "We view the July 26, 2026 FUROSCIX ReadyFlow Autoinjector PDUFA as an underappreciated catalyst with the potential to materially improve both the growth and profitability of MNKD’s owned-product portfolio. Approval would transform FUROSCIX from a five-hour wearable infusion into a simple autoinjector that administers an 80 mg dose in under ten seconds, which we believe could accelerate conversion of existing patients, broaden use earlier in fluid-overload episodes, and materially lower manufacturing costs. With ~85% of current patients expected to prefer ReadyFlow

MannKind raises $50M in private placement led by Frazier Life Sciences

Fri, 24 Jul 2026 06:35:11 -0400

MannKind Corporation (NASDAQ: MNKD) announced a $50 million private placement to certain institutional investors, with closing expected on or about July 24, 2026, subject to customary closing conditions, according to a press release.

The offering was led by Frazier Life Sciences. Under the terms of the securities purchase agreement, MannKind is selling 10,440,838 shares of common stock at $3.89 per share. In lieu of common stock, certain investors may purchase pre-funded warrants for up to 2,412,632 shares at $3.88 per warrant, with an exercise price of $0.01 per share.

MannKind said it intends to use net proceeds for general corporate purposes, including

MannKind Announces $50 Million Private Placement

Fri, 24 Jul 2026 06:35:00 -0400

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it has entered into a securities purchase agreement in connection with a private placement to certain institutional investors. The gross proceeds from the private placement financing are expected to be approximately $50 million. The closing of the financing is expected to occur on or about July 24, 2026, subject to the satisfaction of customary closing conditions.

The private placement

MannKind Announces $50 Million Private Placement

Fri, 24 Jul 2026 06:35:00 -0400

The private placement

MannKind Announces $50 Million Private Placement

Fri, 24 Jul 2026 06:35:00 -0400

The private placement

MannKind Announces $50 Million Private Placement

Fri, 24 Jul 2026 06:35:00 -0400

The private placement

FDA approves MannKind autoinjector for heart failure edema

Fri, 24 Jul 2026 06:30:14 -0400

MannKind Corporation (Nasdaq: MNKD) announced that the U.S. Food and Drug Administration has approved Furoscix ReadyFlow (furosemide injection), an autoinjector for the treatment of edema in adults with heart failure or chronic kidney disease.

According to the company, Furoscix ReadyFlow delivers an 80 mg/mL furosemide dose subcutaneously in under 10 seconds, with the company claiming IV-equivalent diuretic exposure based on comparisons of pharmacokinetic and pharmacodynamic endpoints. Clinical data supporting the approval showed the product achieved its primary pharmacokinetic endpoint and demonstrated equivalent urine output, sodium excretion, and potassium excretion at 6, 8, and 12 hours compared to intravenous furosemide.

The device is

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic K

Fri, 24 Jul 2026 06:30:00 -0400

Transformative delivery option that may support earlier management of worsening fluid overload with a self-administered option designed for use outside the hospital setting
Delivers IV-equivalent diuretic effect through a simple, ready-to-use autoinjector
Provides an 80 mg/mL furosemide dose in a single administration in under 10 seconds
Symptom relief may begin in an hour or less
Conference call and webcast scheduled for July 24 at 9:00 a.m. ET

WESTLAKE VILLAGE, Calif., and BOSTON, July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic K

Fri, 24 Jul 2026 06:30:00 -0400

Transformative delivery option that may support earlier management of worsening fluid overload with a self-administered option designed for use outside the hospital setting
Delivers IV-equivalent diuretic effect through a simple, ready-to-use autoinjector
Provides an 80 mg/mL furosemide dose in a single administration in under 10 seconds
Symptom relief may begin in an hour or less
Conference call and webcast scheduled for July 24 at 9:00 a.m. ET